Thursday, September 16, 2021
Third Pfizer Covid vaccine produces 10 TIMES more antibodies than second jab, Israeli study finds
Medics at Sheba Medical Center in Ramat Gan, outside Tel Aviv, compared the antibody levels in staff one week after their third and second doses.
They found that the Pfizer vaccine — which Israel is solely relying on for its immunisation programmes — stimulated a tenfold greater immune response.
While the research only looked at healthcare staff at one specific hospital, it is hoped that the findings will apply more broadly to the rest of the population.
The hospital said it was treating the results with caution and would be monitoring staff in the coming months to see how long the boost to immunity lasts.
Antibodies are just one part of the overall immune response to Covid, which also includes white blood cells known as T cells that give longer protection.
It comes just a day after the UK finally signed off on a mass booster campaign for 30million over-50s, health and social care staff and Britons with severe health issues.
Israel became the first country in the world to roll out third doses in August, initially inviting over-60s but later gradually opening it up to everyone over the age of 12.
Nearly 3m Israelis have been 'boosted' so far and the country but officials in the UK believe younger people are still enjoying very high protection.
Israel had led the way with the original vaccine rollout last December, becoming the fastest country in the world to vaccinate everyone who wanted a jab.
The trail-blazing programme suppressed the virus by summer which allowed it to become one of the first nations to lift all pandemic restrictions.
But cases began to soar over the summer, due to a combination of vaccines waning and the new Delta variant, which infects vaccinated people more easily.
Israel is set to begin preparations to administer fourth doses of the coronavirus vaccines already,
The country's national coronavirus czar Salman Zarka said last week that the country needs to prepare for a fourth injection, which could be modified to better protect against new variants of the virus.
'Given that that the virus is here and will continue to be here, we also need to prepare for a fourth injection,' he told Kan public radio. 'This is our life from now on, in waves.'
'It seems that if we learn the lessons from the fourth wave, we must consider the [possibility of subsequent] waves with the new variants, such as the new one from South America,' he said at the time.
'Thinking about this and the waning of the vaccines and the antibodies, it seems every few months — it could be once a year or five or six months — we'll need another shot.'
He added that he expects Israel to be given out vaccines that had been specially adapted to cope with different variants of the virus by late 2021 or early 2022.
While Israel is seeing record case numbers in its fourth wave, the jabs are still protecting against severe illness with Covid deaths running at about half of the level of its second wave.
Israel pulled the trigger on a booster vaccine programme in August, which has stabilised the spiralling outbreak.
The country recorded 136 hospital admissions in the week to September 12, down from the peak of 165 in the last week of August. Weekly hospitalisations had soared from just four in June.
Cases continue to rise but this is believed to be due to a big testing blitz in schools, which went back at the start of the month.
Infections also remain very low among the triple-jabbed, the country's health ministry said.
The results in Israel will likely have inspired UK health officials to green light a booster programme.
But they have stopped short of recommending third doses to the entire population, with shots being reserved for the roughly 32m deemed most vulnerable to Covid.
It will start next week and Britons will only be invited for a booster six months after getting their second jab.
That appears to be the 'sweet spot', according to officials who signed off on the move due to waning immunity.
That decision is largely in line with Israel's programme, which is only offering third doses to people five months after their second.
However, MailOnline revealed today that only 1.6million people in the UK, mainly care home residents and frontline health workers, were fully vaccinated by March 15 - the cut off point to qualify for a booster.
The UK didn't breach the 30million mark until June, meaning the campaign won't be open to millions of vulnerable adults until much closer to Christmas.
Experts told MailOnline the decision to delay boosters by six months should not be a cause for concern because the gap means people are only given a top-up dose as their immunity starts to wane.
But they warned it could be a problem for a 'small number' of older and vulnerable people whose immunity drops faster than expected.
Booster doses of the Pfizer jab, or a half dose of Moderna, will be administered to those eligible from next week, regardless of which jab they initially received.
For those who cannot get either of those two mRNA jabs, such as due to an allergy, they will be given a dose of AstraZeneca's vaccine.
The jabs will be dished out through vaccination centres, primary care networks and pharmacies and can be given at the same time as annual flu jabs.
Department of Health bosses said the booster campaign will 'ensure the protection vaccines provide for those most at risk of severe illness from Covid will be maintained over the winter months'.
Pfizer's jab, made alongside German partner BioNTech, is already approved for over-12s in Britain.
It is the first phase of the Government's winter plan to avoid another lockdown. If hospitalisations rise quickly, ministers have warned they could be forced to reintroduce face masks and work from home guidance.
Dr Doug Brown, chief executive at the British Society of Immunology, told MailOnline: 'Receiving two vaccinations against Covid has been shown to be highly effective at preventing severe disease, hospitalisation and death as well as generating an effective immune response that does provide this protection in the long term.
'We don’t yet know exactly how long immunity will last, which is why the government’s decision to offer booster doses to the most vulnerable is a welcome move which will help us be prepared for the worst this winter.
'With the third dose being offered six months after the second, studies have shown that we can be confident that for those six months people will have protection during that period from their initial vaccinations with the third dose providing an additional boost to the immune system.
'In addition to boosters, we must not take our foot off the gas and continue to make every effort to reach people who have not had their first doses of the vaccine and encourage them to come forward for a Covid vaccination. 'Vaccination is our only way out of this pandemic.'
Earlier this month, half a million severely immunosuppressed people, who are most at-risk from Covid and were unable to mount a full response to the vaccine, were invited to get a third dose.
*************************************************
Clinical trial to test whether anti-parasite drug ivermectin is effective at treating Covid set to begin in Minnesota
Clinical trials will soon begin in Minnesota to test whether or not anti-parasite drug ivermectin is effective at treating COVID-19.
The University of Minnesota Medical School will be examining the drug along with two others to determine their effectiveness at combatting the virus.
Ivermectin is approved by the U.S. Food and Drug Administration (FDA) for human use to treat certain parasite-related conditions, and it is regularly available by prescription.
However, many are harming themselves because they are purchasing versions of the drug meant for large animals like cows and horses at livestock stores and consuming doses of that are too large to be considered safe for humans.
Researchers are currently recruiting participants for the study. To be eligible, a person must be between ages 30 and 85 and have tested positive for COVID-19 n the past three days.
People who are currently hospitalized for any reason, or are taking metformin, insulin, sulfonylurea or have heart, liver of kidney disease are not eligible.
As an incentive, anyone who participates will be offered $400.
Those who are chosen for the study will be placed into one of six groups, each of which will be using a different set of drugs for treatment. One group will receive ivermectin alone and another will get a combination of ivermectin and metformin, a drug used to treat type 2 diabetes.
A third group will be given metformin alone, the fourth group will receive fluvoxamine - a drug that treats obsessive compulsive disorder - and a fifth group will receive a combination of those two drugs.
The sixth and final group will receive a placebo.
Researchers hope they can either discover new potential treatments for Covid, or rule these drugs out entirely as ineffective.
All three are already FDA approved for human use, though not for viruses.
Ivermectin garnered attention of social media as a potential Covid treatment after an Australian study found the drug could inhibit replication of the virus's cells.
Dr Timothy Geary, a parasitologist at McGill University in Montreal, Canada, and one of the world's foremost experts on the drug, explained to DailyMail.com in an interview last month that the study was being misinterpreted.
'In that study they showed that in cell cultures, ivermectin could inhibit [Covid] replication, but the concentrations required for that effect were in a range called the micromolar range - very high concentrations relative to what you would find in the plasma of a treated person or an animal, which would be 20 to 50 times lower,' he said.
'At high concentrations in cell culture, many compounds can have all kinds of effects but when you look at what we would call pharmacological levels - what we actually see and treated patients - it is far higher than [what would be used in humans]
'So the standard doses of ivermectin that we use for people are never going to reach the levels that would be effective in against the virus based on that one study.'
Many have used the drug inappropriately to protect themselves from the virus, however.
There has been a 24-fold increase in prescriptions for the drug compared to before the pandemic began, a CDC report from last month found.
Those prescriptions are generally safe, however, because they are of human versions of the drug.
Where people are running into problems is when they purchase veterinary versions of the drug, which come in doses much larger than what is safe for humans - and overdose.
This has led to a spike in calls to poison control in recent months, and many local and federal officials issuing warnings against use of the drug.
************************************
Also see my other blogs. Main ones below:
http://edwatch.blogspot.com (EDUCATION WATCH)
http://antigreen.blogspot.com (GREENIE WATCH)
http://pcwatch.blogspot.com (POLITICAL CORRECTNESS WATCH)
http://australian-politics.blogspot.com/ (AUSTRALIAN POLITICS
http://snorphty.blogspot.com/ (TONGUE-TIED)
*************************************
Wednesday, September 15, 2021
Britain's Test and Trace system has had barely any impact on thwarting the spread of Covid, according to official estimates.
The controversial £37billion scheme has been heavily criticised over the past year for being ineffective at breaking the chains of transmission.
New Government modelling found the programme – which critics have described as being the biggest ever waste of taxpayer money – may have only slashed cases by as little as six per cent.
It also estimates that people isolating prevented 1.2million to 2million secondary cases, with NHS Test and Trace responsible for stopping 300,000 to 500,000 of these.
The estimate assumed people with Covid symptoms and their households would still have isolated if testing wasn't on offer.
But health chiefs noted that without the offer of testing, millions more people would have needlessly self-isolated when they weren't infected because they wouldn't have been able to prove they were negative through a swab.
Test and Trace identified around 900,000 positive cases in August, according to official figures.
It comes as Boris Johnson will today warn that the pandemic is 'far from over' as he unveils his 'winter plan, admitting that another lockdown cannot by completely ruled out.
A report published by NHS Test and Trace looked at what impact it had over and above if people with symptoms still isolated without any access to testing.
It did this by analysing the transmission reduction from testing, tracing and isolating from the current scheme.
This was then compared to an imagined scenario where testing was not on offer and households were told to self-isolate if someone developed Covid symptoms.
A panel including 'Professor Lockdown' Neil Ferguson, an epidemiologist at Imperial College London, helped with the modelling.
The study, which looked at the period from last August to April, found the Test and Trace scheme reduced transmission between 10 and 28 per cent.
Will Boris's winter plan be enough to avert lockdown?
Boris Johnson will today warn that the pandemic is 'far from over' as he unveils his 'winter plan' - admitting that another lockdown cannot by completely ruled out.
The PM is set to flesh out his strategy in a press conference this afternoon, after Health Secretary Sajid Javid has given the outline to MPs in a statement.
He will insist that vaccines can be the main defence against the disease, with boosters for the over-50s and jabs for under-16s starting soon.
But blueprint includes the return of compulsory masks, working from home and some social distancing if the NHS is under threat. Vaccine passports will still be an option, even though they will not be introduced in England from next month as originally intended.
And health minister Nadhim Zahawi said this morning that lockdown is on the table as a 'last resort' if infections run completely out of control.
Scientists are already warning that the country is going into the winter with high levels of cases, saying that 'does not bode well' for hopes of avoiding further restrictions.
But if people stayed at home when they suspected they had the virus anyway, like they are supposed to, the testing system only reduced transmission from six to 19 per cent.
However, the report claimed the T&T system was 'critical' in reducing the R rate – a measure of how quickly the virus is spreading – and bringing it below one.
It told 11million people to isolate during the study period.
However, the report warns that the data gives a 'very high-level view of the impact of the whole system', so should not be used to evaluate its specific components.
And it notes that testing and contact tracing may have prevented outbreaks in other settings, such as from hospitals, which were not included in the figures.
It also warned it is 'extremely difficult to estimate how people would really behave' if testing was not in place, so the numbers it assumed would isolate without testing may be overstated and underestimate the impact of Test and Trace.
NHS Test and Trace has contacted more than 14.9million infected people in England and their close contacts and processed over 262million tests since it was launched last June.
Between last August and April, the programme identified between 25 and 65 per cent of infected Britons and their close contacts.
The Department of Health and Social Care said: 'Since its inception, NHS Test and Trace has played an important role in countering this virus – along with the phenomenal vaccination programme – contacting over 14.9million people from across the country and breaking chains of transmission to stop outbreaks.
'With around one in three people with Covid showing no symptoms, regular testing and contact tracing, alongside the wall of defence built by the vaccination programme, are fundamental to ongoing efforts to keep people safe and help the return to a more normal way of life.'
It comes as the Prime Minister is set to flesh out his strategy in a press conference this afternoon, after Health Secretary Sajid Javid has given the outline to MPs in a statement.
He will insist that vaccines can be the main defence against the disease, with boosters for the over-50s and jabs for under-16s starting soon.
Boris Johnston said yesterday: 'The pandemic is far from over, but thanks to our phenomenal vaccine programme, new treatments and testing we are able to live with the virus without significant restrictions on our freedoms.'
https://www.dailymail.co.uk/news/article-9988617/37billion-Test-Trace-scheme-cut-6-Covid-cases.html
*******************************************Britain is preparing for a long, virulent winter without a single lockdown. Can they pull it off?
British Prime Minister Boris Johnson is backing booster COVID-19 vaccine shots for vulnerable people and the elderly as part of his plan to prevent hospitals being overwhelmed and future lockdowns as the UK approaches winter.
The prime minister is hoping to avoid a winter like last year, when a second wave fuelled by the Alpha variant caused more than 50,000 deaths on either side of the peak in mid-January 2021.
On Monday, it was announced England's vaccine rollout will expand to those aged between 12 and 15, and on Tuesday it was revealed in the government's 32-page plan that booster shots will be available for those over the age of 50, frontline health workers and the clinically vulnerable – estimated to be around 30 million people.
As well as booster jabs, the government has prepared a "plan B" in the event hospitalisations rise dramatically and the National Health Service is put at risk of being overwhelmed, which could involve mandatory facemask wearing, vaccine passports and a return of working from home.
With another 26,628 people testing positive for COVID-19 and a further 185 deaths recorded on Tuesday, Mr Johnson said in one way the UK was in a more challenging position than it was at the same time last year, when cases hovered around 3,000 per day.
"But in many other crucial respects, the British people – all of us collectively and individually – are incomparably better placed to fight the disease," he said. "We have more than 80 per cent of all over 16s now double vaccinated, and we have COVID anti-bodies in around 90 per cent of the adult population. "Those vaccines are working."
So how exactly is Boris Johnson's government going to prevent another deadly winter?
The UK is backing vaccines to do the heavy lifting over the winter months, with transmission likely to increase as students go back to school, workers return to workplaces and people spend more time indoors as the days get shorter and colder.
Earlier on Tuesday, England's Deputy Chief Medical Officer, Johnathan Van Tam, said vaccines had saved 112,000 lives since being rolled out at the end of last year.
"Our latest estimates are that since we began deploying these vaccines, they've probably averted in the region of 24 million cases of COVID in the UK and 112,000 deaths — so, incredibly successful to date and remains so," Professor Van-Tam said.
"We're not past the pandemic — we're in an active phase still. "We know this winter could quite possibly be bumpy at times."
Along with advising children aged between 12 and 15 get vaccinated, the Joint Committee on Vaccines and Immunisation made the recommendation to deploy booster shots across all four nations in the UK, which will be given at least six months after people had received their second dose of the vaccine.
It said there was evidence of a small decline in effectiveness of the vaccine against hospitalisation for older people, dropping from just over 90 per cent to just under 90 per cent after five to six months. "We've been seeing some waning immunity (in older people)," Dr Robertson said.
"But really, I think what they're trying to do is look forward and look what could happen in the future. and mitigate against that."
At the peak of the pandemic last winter, England alone had more than 30,000 patients in hospitals with COVID-19. Currently there are just over 8,400 across the UK, and the biggest concern for the government remains that figure rising dramatically and the NHS becoming overwhelmed, which would see an increase in deaths from COVID-19 and other causes that would not be able to be treated.
If numbers do start rising, the public will be urged to act more cautiously, face coverings could become legally mandated in settings such as indoors and on public transport, and mandatory vaccine passports could be introduced for large events and other indoor settings.
"The thing I would stress about Plan B is that it contains a number of different shots in the locker and you wouldn't necessarily play them all at once, far from it," Mr Johnson said.
"Because so many of the population have some degree of immunity, smaller changes in the way we're asking people to behave can have a bigger impact."
No more lockdowns?
On Monday, the UK's Telegraph newspaper quoted a senior government source as saying Mr Johnson was "dead set" against another lockdown, as rumours swirled that plans were being drawn up for an October "firebreak" lockdown to try and quell infections.
While there is scant detail of lockdown contingencies in the government's winter plan, on Monday, a Downing Street spokesperson conceded the strategy could not be ruled out if things got out of hand.
Mr Johnson was criticised several times in 2020 for delaying nationwide lockdowns as the virus tore through the country.
But with the success of the vaccines, the prime minister will be loathe do go down the lockdown route again over winter.
************************************
Also see my other blogs. Main ones below:
http://edwatch.blogspot.com (EDUCATION WATCH)
http://antigreen.blogspot.com (GREENIE WATCH)
http://pcwatch.blogspot.com (POLITICAL CORRECTNESS WATCH)
http://australian-politics.blogspot.com/ (AUSTRALIAN POLITICS
http://snorphty.blogspot.com/ (TONGUE-TIED)
*************************************
Tuesday, September 14, 2021
India may be reaching 'endemicity' after emerging from second COVID-19 wave
The number of new COVID-19 cases and deaths in India has dropped dramatically since a second wave of the virus peaked in May.
First the Alpha and then the Delta variant — which was first detected in India and is now causing strife elsewhere in the world — ravaged the country.
But the seven-day average of daily reported cases this week is just a tenth of the 400,000 recorded during the peak.
Reported deaths are down, too, with an average of fewer than 500 per day, down from more than 4,000 per day.
According to health authorities, more than 439,000 people in India have now died with the virus.
The relatively stable numbers, which lasted throughout August, prompted the World Health Organization's chief scientist to suggest India may have reached a state of "endemicity".
That is, it may be endemic or constantly present in a particular place.
So how did they get there and is the worst of the pandemic over for India?
What is it like in India at the moment?
While the usual caveats apply about numbers being underestimated due to inadequate testing and reporting, it's clear that things have improved India-wide.
In May, Delhi's health system was completely overwhelmed, with medical oxygen supplies exhausted, leading to distressing images of makeshift outdoor crematoriums.
This week, less than 2 per cent of Delhi's COVID-19 beds were occupied.
Business has picked back up and schools are reopening in some states.
Soumyadeep Bhaumik, from the George Institute India in New Delhi, said the health system was now "functioning normally" and focusing on vaccination.
However, he said, life was not back to a pre-COVID normal.
Cases were low across most of India but there had been a surge in Kerala in the past few days, he said.
"There is no 'lockdown' now but movement restrictions appropriate to the transmission are now being implemented in different states in India," he told the ABC.
"Kerala has more restrictions now because cases are increasing, but other states, which have low cases, have fewer."
How did India get out of the Delta wave?
While India's federal government did not implement a nationwide lockdown during the second wave, by mid-May almost all of India's 36 states and territories had instituted full or partial lockdowns.
Other countries such as the UK, the Netherlands and Israel saw sharp declines in cases as a consequence of high vaccination rates and high infection levels.
In India, only about 10 per cent of the population are fully vaccinated, while about 36 per cent of people have had at least one shot.
However, a serology survey conducted in June and July indicated two out of three people in India had COVID-19 antibodies.
"The massive community spread in COVID-19 in the second wave earlier this year meant a lot of people were exposed — symptomatic or otherwise," Dr Bhaumik said.
"It also created awareness about the need to wear masks, avoiding crowds et cetera."
University of Cambridge researcher Ankur Mutreja told the ABC the combination of the state lockdowns and the increase in natural immunity combined to flatten the curve.
"While lockdowns hammer the curve directly, natural exposure during leaky lockdowns facilitates that hammering," Dr Mutreja said.
He said the high rate of antibodies from exposure was helping to keep a lid on the situation for the moment.
"Vaccination rates have also increased massively in India since the second wave, with more than 10 million doses being administered each day for the last few days," he said.
Conspiracy theories about ivermectin and hydroxychloroquine
A conspiracy theory going around at the moment is that India began treating people en masse with hydroxychloroquine or ivermectin and that was responsible for the fall in cases and deaths.
AAP fact checked the claim and found it was baseless.
"There is no evidence that new guidance on the use of ivermectin and hydroxychloroquine led to a reduction in COVID-19 cases in India," they found.
"In fact, hydroxychloroquine was reported to be in widespread use well prior to the country's second-wave outbreak."
Experts — including the ivermectin's manufacturers — have repeatedly said there was no evidence the drugs were effective in treating COVID-19.
'We may be entering some stage of endemicity'
WHO chief scientist Soumya Swaminathan late last month told The Wire that while India would probably experience a third wave, it would likely not be as severe as the second.
"We may be entering some kind of stage of endemicity, where there is low-level transmission or moderate-level transmission going on but we are not seeing the kinds of exponential growth and peaks that we saw a few months ago," Dr Swaminathan said.
India would continue to have "ups and downs in different parts of the country" in areas that were less affected in the first and second waves or with lower levels of vaccine coverage, she said.
That's why Kerala, which was less affected during the second wave, was experiencing a surge now, she said.
David Anderson, from the Burnet Institute in Melbourne, said "endemic" normally just meant that a disease was always present in a population.
"That means that if you have a susceptible population, whether they're unvaccinated or they haven't been infected previously, it can find them and infect them," he said.
He said whether an endemic virus could be managed well enough to prevent an unacceptable loss of life was another question.
He said he didn't believe having two-thirds of the population vaccinated or with antibodies from COVID-19 infections was enough to prevent exponential growth.
Either more people had been exposed to the virus than the serology surveys indicated or the impact of the virus now was being under-reported, or both, he said.
"I can't help but think that in India, they must still be having quite high rates of infection, but people are just not seeking care to the same degree," he said.
What does the future hold?
Since May India's state and federal governments have put more resources into public education on social distancing, tightened the borders, hired more health workers, set up new medical oxygen plants, stockpiled medicines for infections such as mucormycosis and beefed up the country's virus tracking system.
The experts contacted by the ABC agreed that India's relative respite from COVID-19 was probably only temporary and a third wave was on its way.
When it will arrive and how severe it will be is up for debate.
Dr Mutreja said vaccination rates had "increased massively" since the second wave, with more than 10 million doses being administered each day for the last few days, but another wave was "imminent".
He said how big it would be depended on how quickly the Delta variant evolved into a "more capable escape variant", the speed of India's vaccination campaign and how effective the vaccines were against the next variant.
Rajib Dasgupta, chair of Jawaharlal Nehru University's Centre of Social Medicine and Community Health, agreed that the combination of increasing vaccination coverage and high levels of immunity acquired through infections was protecting much of the population.
************************************************
New vaccine coming from Australia
Works with Delta
Speaking at an online scientific symposium on Friday, UQ Professor Paul Young said they were well down the road to developing a new version of their vaccine candidate, using the same molecular clamp technology.
Professor Young told the meeting that after the initial version 1.0 vaccine was abandoned in December 2020 because of cross-reactivity issues with HIV screening tests, he fully expected the international funding body that initially backed the research, to request he and his team move on to other projects.
However, in a Zoom call shortly after announcing to the world that they had failed in their initial push for an Australian-developed COVID-19 vaccine, the vaccine’s backers told him to go back and try again.
“When I got on that Zoom meeting, there were 126 people there,” he said.
“Having seen our phase one clinical data, they were unanimous with wanting us to stay focused on COVID. So, we have done that, and we are taking a new COVID vaccine forward.”
Version 1.0 had performed well in the initial clinical trials, giving well over 90 per cent coverage against the Wuhan strain of the virus, using a molecular “clamp” to hold a protein in a shape that mimicked part of the spike protein seen on the outside of SARS-CoV-2, which caused the body to make antibodies for the virus.
However, the actual clamp molecule used was sourced from the HIV virus because it was very effective and the researchers didn’t have time to look for a better candidate.
Although there was no risk of contracting HIV from the small molecule, it did set off HIV screening tests, something the researchers did not initially think would happen.
“What tipped us over in the end was not wanting to cause vaccine hesitancy,” he said. “And so the right decision was made at that particular time. Whether that was the right decision, given the fullness of time, I don’t know.
“But we’ve turned it around and found a successful alternative, so that we’re very pleased with, and we will progress with that.”
Professor Young said they had developed around 20 new versions of the vaccine, using a different molecule for the “clamp” used to hold the spike protein together.
He said they would be entering clinical trials in 2022, with work being done on animal models in the near future.
“Not surprisingly, we’re looking at a number of different variants including Delta, and the new clamp is working well,” he said.
******************************************
IN BRIEF
Voters rightly concerned trillions in domestic spending will fuel inflation (Free Beacon)
House Democrats propose making permanent expanded ObamaCare subsidies (The Hill)
FBI releases declassified records on its investigation into possible Saudi-9/11 links (Washington Examiner)
North Korea tests first cruise missile with possible nuclear capability (Reuters)
A trip down memory lane: Biden administration promised it wouldn’t mandate COVID vaccine (The Federalist)
Jen Psaki admits vax mandate doesn’t include migrants at border, refuses to answer why (Daily Wire)
Apple must change its tightly controlled App Store, judge rules (NPR)
Portland callers to 911 more often on hold for over five minutes as calls rise, staff drops (The Oregonian)
Dumb… Salesforce CEO says he’ll move workers out of Texas due to abortion law, yet California-based businesses have been flocking to Texas to escape higher taxes and regulations (Fox Business)
Capitol Police recommend disciplinary action for six officers after internal investigation into January 6 riot (CBS News)
Russia completes construction of Biden-approved Nord Stream 2 gas pipeline (NBC News)
Policy: Compassionate enforcement: Cities must balance public services with public order to reduce homelessness (City Journal)
Policy: Seven hard truths Americans should know about Social Security — and five ways to strengthen it (Heritage Foundation)
************************************
Also see my other blogs. Main ones below:
http://edwatch.blogspot.com (EDUCATION WATCH)
http://antigreen.blogspot.com (GREENIE WATCH)
http://pcwatch.blogspot.com (POLITICAL CORRECTNESS WATCH)
http://australian-politics.blogspot.com/ (AUSTRALIAN POLITICS
http://snorphty.blogspot.com/ (TONGUE-TIED)
*************************************
Note:
I have just put up another post on my Food and Health blog. It is about a partial cure for Alzheimers
*************************************
Monday, September 13, 2021
Surge in Covid cases in those vaxxed - but it could have its benefits
Many people are worried about reports of “breakthrough” Covid-19 infections overseas, from places like Israel and the United States.
A breakthrough infection is when someone tests positive for Covid after being fully vaccinated, regardless of symptoms.
The good news is most breakthrough infections usually result in mild symptoms or none at all, which shows us that vaccines are doing exactly what they’re supposed to do — protecting us from severe disease and death. Vaccines aren’t designed to protect us from getting infected at all (known as “sterilising immunity”).
People with breakthrough infections can go on to infect others. Preliminary evidence indicates immunised people can have high levels of virus in the nose, potentially as high as unvaccinated people.
Life has returned to some normality in many vaccinated countries, despite thousands of new cases. Source: Getty
Life has returned to some normality in many vaccinated countries, despite thousands of new cases. Source: Getty
However, if you’re vaccinated you’ll clear the virus more quickly, reducing the length of time you’re infectious and can pass the virus on.
Here’s why breakthrough cases are happening, and why you shouldn’t worry too much.
Waning immunity
Two studies from the United Kingdom suggest the immunity we get from Covid vaccines wanes over time, after about four to six months.
While the more-infectious Delta variant continues to circulate, waning immunity will lead to more breakthrough infections.
But the reduction isn’t large currently. Vaccine effectiveness is very high to begin with, so incremental reductions due to waning won’t have a significant effect on protection for some time.
Israeli data shows some vaccinated people are becoming ill with Covid. But we need to keep in mind Israel’s vaccine rollout began in December 2020, and the majority of the population were vaccinated in early 2021. Most are now past six months since being fully vaccinated.
Given most people in Israel are vaccinated, many Covid cases in hospital are vaccinated. However, the majority (87 per cent) of hospitalised cases are 60 or older. This highlights what’s known about adaptive immunity and vaccine protection — it declines with age.
Therefore we’d expect vulnerable groups like the elderly to be the first at risk of disease as immunity wanes, as will people whose immune systems are compromised. Managing this as we adjust to living with Covid will be an ongoing challenge for all countries.
What would be concerning is if we started seeing a big increase in fully vaccinated people getting really sick and dying — but that’s not happening.
Globally, the vast majority of people with severe Covid are unvaccinated.
We’ll probably need booster doses
Waning immunity means booster doses will likely be needed to top up protection, at least for the next couple of years while the virus continues to circulate at such high levels.
Our currently approved vaccines were modelled on the original strain of the virus isolated in Wuhan, not the Delta variant, which is currently dominant across most of the world. This imperfect match between vaccine and virus means the level of protection against Delta is just a little lower.
Because the level of effectiveness is so high to begin with, this small reduction is negligible in the short term. But the effects of waning over time may lead to breakthrough infections appearing sooner.
mRNA vaccines in particular, like Pfizer’s and Moderna’s, can be efficiently updated to target prevalent variants, in this case Delta. So, a third immunisation based on Delta will “tweak”, as well as boost, existing immunity to an even higher starting point for longer-lasting protection.
We could see different variants become endemic in different countries. One example might be the Mu variant, currently dominant in Colombia. We might be able to match vaccines to whichever variant is circulating in specific areas.
The dose makes the poison
Your level of exposure to the virus is likely another reason for breakthrough infections.
If you’re fully vaccinated and have merely fleeting contact with a positive case, you likely won’t breathe in much virus and therefore are unlikely to develop symptomatic infection.
But if you’re in the same room as a positive case for a long period of time, you may breathe in a huge amount of virus. This makes it harder for your immune system to fight off.
This may be one reason we’re seeing some health-care workers get breakthrough infections, because they’re being exposed to high viral loads. They could be a priority for booster doses.
Might unvaccinated kids be playing a role?
It’s unclear if children are contributing to breakthrough infections.
Vaccines aren’t approved for young children yet (aged under 12), so we’re seeing increasing cases in kids relative to older people. Early studies, before the rise of Delta, indicated children didn’t significantly contribute to transmission.
More recent studies in populations with vaccinated adults, and where Delta is the dominant virus, have suggested children might contribute to transmission. This requires further investigation, but it’s possible that if you’re living with an unvaccinated child who contracts Covid, you’re likely to be exposed for many, many hours of the day, hence you’ll breathe in a large amount of virus.
The larger the viral dose, the more likely you’ll get a breakthrough infection.
Potentially slowing the number of breakthrough infections is one reason to vaccinate 12 to 15 year olds, and younger children in the future, if ongoing trials prove they’re safe and effective in this age group. Another is to protect kids themselves, and to get closer to herd immunity (if it’s achievable).
A silver lining
Breakthrough infections likely confer extra protection for people who’ve been fully vaccinated — almost like a booster dose.
We don’t have solid real-world data on this yet, but it isn’t surprising as it’s how our immune system works. Infection will re-expose the immune system to the virus’ spike protein and boost antibodies against the spike.
However, it’s never advisable to get Covid, because you could get very sick or die. Extra protection is just a silver lining if you do get a breakthrough infection.
As Covid becomes an endemic disease, meaning it settles into the human population, we’ll need to keep a constant eye on the interaction between vaccines and the virus.
The virus may start to burn out, but it’s also possible it might continually evolve and evade vaccines, like the flu does.
*******************************************
Denmark ditching all Covid restrictions – except one
Denmark has become the first European country to lift all domestic Covid-19 restrictions after vaccinating 80 per cent of all people over the age of 12.
Danish minister of health Magnus Heunicke declared the pandemic is “under control” due to high rates of vaccination in Denmark and the virus is no longer a “critical threat to society”.
“The government has promised not to hold on to the measures any longer than was necessary, and there we are now,” Mr Heunicke said.
The move was approved in late August with all restrictions officially scrapped from today.
Danes no longer need to show a “Covid pass” to enter restaurants, sports centres, nightclubs or large events. Schools have reopened, with children no longer being sent home if they come into close contact with a confirmed case.
Only those infected have to quarantine and workers can go back to the office as normal.
However, it’s not a complete return to pre-pandemic life.
Restrictions around borders and travel remain in place for now because they are controlled by a separate political agreement, which is set to expire at the end of October. Denmark’s border rules currently allow most people who can prove they are fully vaccinated or can present a negative test to visit the country.
Double-dosed Americans and Canadians can enter Denmark for any purpose. Those not considered to be fully immunised must present a negative test result and must also take a test upon arrival.
But the threat of restrictions being re-implemented still looms if the health system becomes overwhelmed with positive cases.
“But even though we are in a good place right now, we are not out of the epidemic. And the government will not hesitate to act quickly if the pandemic again threatens important functions in our society,” Mr Heunicke said.
https://au.yahoo.com/news/european-country-denmark-ditching-covid-restrictions-085649956.html
******************************************Also see my other blogs. Main ones below:
http://edwatch.blogspot.com (EDUCATION WATCH)
http://antigreen.blogspot.com (GREENIE WATCH)
http://pcwatch.blogspot.com (POLITICAL CORRECTNESS WATCH)
http://australian-politics.blogspot.com/ (AUSTRALIAN POLITICS
http://snorphty.blogspot.com/ (TONGUE-TIED)
*************************************
Sunday, September 12, 2021
The Mu variant is on the rise. Scientists weigh in on how much to worry
Laboratory studies suggest this variant may be better at avoiding the immune system but lags Delta when it comes to transmission and infecting cells.
One of the newest variants of COVID-19, known as Mu, has spread to 42 countries, but early studies suggest that it is less easily transmitted than the dangerous Delta variant, which has triggered a resurgence of the pandemic in the U.S. and many other countries.
Mu quickly became the dominant strain in Colombia, where it was first detected in January, but in the U.S., where the Delta virus is dominant, it has not spread significantly. After reaching a peak at the end of June, the prevalence of the Mu variant in the U.S. has steadily declined.
Scientists believe that the new variant cannot compete with the Delta variant, which is highly contagious. “Whether it could have gone higher or not if there was no Delta, that's hard to really say,” says Alex Bolze, a geneticist at the genomics company Helix.
In Colombia, however, the Mu variant is responsible for more than a third of the COVID-19 cases. There have been 11 noteworthy variants to date, which the World Health Organization has named for the letters of the Greek alphabet. The newest variant, Mu, is the 12th. WHO has labeled this latest version of SARS-CoV-2 a Variant of Interest, a step below a Variant of Concern.
Delta and three other variants have drawn the highest level of concern. But a Variant of Interest, like Mu still raises worries. Mu has many known mutations that can help the virus escape immunity from vaccines or previous infection.
Still, the good news is that Mu is unlikely to replace Delta in places like the U.S. where it is already predominant, says Tom Wenseleers, evolutionary biologist and biostatistician at the Catholic University of Leuven in Belgium, who previously estimated the transmissibility and impact of Alpha variant in England.
How is Mu different?
Most genetic sequences reveal that Mu has eight mutations in its spike protein, many of which are also present in variants of concern: Alpha, Beta, Gamma, and Delta.
Some of Mu’s mutations, like E484K and N501Y, help other variants evade antibodies from mRNA vaccines. In the Beta and Gamma variants, the E484K mutation made the variants more resistant to a single dose of mRNA vaccines.
A study, not yet peer reviewed, has shown that the P681H mutation helps transmission of the Alpha variant—it may do the same for Mu.
Mu also harbors novel mutations that haven’t been seen in variants before, so their consequences are not fully understood. Mutation at the 346 position disrupts interaction of antibodies with the spike protein, which, scientists say, might make it easier for the virus to escape.
A study using epidemiological models, not yet peer reviewed, estimates that Mu is up to twice more transmissible than the original SARS-CoV-2 and caused the wave of COVID-19 deaths in Bogotá, Colombia in May, 2021. This study also suggests that immunity from a previous infection by the ancestral virus was 37 percent less effective in protecting against Mu.
“Right now, we do not have [enough] available evidence that may suggest that indeed this new variant Mu is associated with a significant [..] change in COVID,” says Alfonso Rodriguez-Morales, the President of the Colombian Association of Infectious Diseases.
But some clues are emerging that Mu can weaken protection from antibodies generated by existing vaccines. Lab-made virus mimicking the Mu variant were less affected by antibodies from people who had recovered from COVID-19 or were vaccinated with Pfizer’s Comiranty. In this study, not yet peer reviewed, Mu was the most vaccine resistant of all currently recognized variants.
In another lab-based study, antibodies from patients immunized with Pfizer’s vaccine were less effective at neutralizing Mu compared to other variants.
“[Mu] variant has a constellation of mutations that suggests that it would evade certain antibodies—not only monoclonal antibodies, but vaccine and convalescent serum-induced antibodies—but there isn’t a lot of clinical data to suggest that. It is mostly laboratory […] data,” said Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, at a White House press briefing on September 2.
The COVID-19 vaccines—Pfizer, Astra Zeneca, Johnson & Johnson, and Sinovac, all of which are available in Colombia—still seem to offer good protection against Mu, according to Rodriguez-Morales.
How prevalent is Mu?
The Mu variant rapidly expanded across South America, but it is difficult to know for sure how far Mu has spread, according to Paúl Cárdenas, microbiologist at Universidad San Francisco de Quito in Ecuador.
“[Latin American countries] have provided very low numbers of sequences, compared with the numbers of cases that we have,” says Cárdenas. South American countries have sequenced just 0.07 percent of their total SARS-CoV-2 positive cases, although 25 percent of global infections have occurred in the region. This contrasts with 1.5 percent of all positive cases sequenced in the U.S. and 9.3 percent of all positive cases sequenced in the U.K.
“We are not necessarily looking at the reality of the distribution of the variants [in Latin America], because of the limitations in performing genome sequencing,” says Rodriguez-Morales.
That said, except in Columbia where Mu has been spreading since late February, the variant is becoming relatively less frequent globally, including in the rest of South America.
“Additional evidence on Mu is scarce, similar to Lambda and other regionally prevalent variants, because of limited capacity for follow-up studies, and because these variants have not yet been a significant threat in high-income countries like Delta is,” says Pablo Tsukayama, a microbiologist at Universidad Peruana Cayetano Heredia in Lima, Peru. He hopes the WHO’s designation of Mu as a variant of interest will change that.
*********************************************
Moderna Announces Development of Combination COVID-19 Booster and Flu Vaccine
Moderna announced on Thursday it had begun development for a potential single-dose vaccine that is a combination of a Wuhan coronavirus vaccine booster shot and seasonal flu shot.
In a press release published Thursday, Moderna CEO Stephane Bancel announced the new development and shared the progress of other programs the company is working on, such as their “cancer vaccine.”
“Today we are announcing the first step in our novel respiratory vaccine program with the development of a single dose vaccine that combines a booster against COVID-19 and a booster against flu,” Bancel said in a statement. “We are making progress on enrolling patients in our rare disease programs, and we are fully enrolled in our personalized cancer vaccine trial. We believe this is just the beginning of a new age of information-based medicines.”
As we previously reported, Moderna informed investors and analysts last month that the company was planning for a booster COVID-19 shot in addition to its already-existing two-dose mRNA vaccine shot. As of right now, the Moderna COVID-19 vaccine was granted Emergency Use Authorization (EUA) by the Food and Drug Administration (FDA) to be administered to prevent the spread of COVID-19. However, the vaccine has not been fully approved by the FDA.
“We are pleased that our COVID-19 vaccine is showing durable efficacy of 93% through six months, but recognize that the Delta variant is a significant new threat so we must remain vigilant,” Bancel said in a statement last month announcing plans for a potential booster shot. In the statement, Bancel also said Moderna is “looking forward towards our vision of a single dose annual booster that provides protection against COVID-19, flu and RSV for adults.”
Perhaps that vision could be on the horizon with this hybrid coronavirus/flu vaccine in the works. Moderna has not revealed when it plans to have the booster shot completed.
****************************************
IN BRIEF
RNC to sue Biden administration over vaccine mandates (Washington Examiner)
“We will fight”: Ron DeSantis promises to battle Biden’s sweeping mandates (Daily Wire)
Pentagon top brass to testify before Senate panel on chaotic U.S. pullout from Afghanistan (Washington Times)
GOP letter to Biden flags Afghan evacuees’ “rushed and incomplete” vetting (Fox News)
Taliban lets plane carrying Americans and other foreign nationals leave Kabul (CBS News)
“Their interior minister has an ‘FBI Wanted’ poster”: White House challenged after calling Taliban “businesslike and professional” (Daily Caller)
New and improved? Hardly: Taliban tortured journalists who covered protests in Kabul despite “free press” pledge (Daily Wire)
Fort Hood terrorist congratulates Taliban from death row in handwritten letter (Washington Examiner)
Merrick Garland’s Justice Department suing Texas over pro-life law (The Federalist)
Rand Paul calls for Anthony Fauci to be jailed for lying to Congress (Washington Examiner)
DOJ moves to release FBI documents on investigation into possible Saudi-9/11 hijacker links (Washington Examiner)
Team Biden puts systemic racism at center of U.S. foreign policy (National Review)
The CDC quietly changed the definition of “vaccination” so as to fit the political narrative (Not the Bee)
FDA declines emergency use authorization for Humanigen COVID-19 drug (The Hill)
https://patriotpost.us/articles/82600-friday-executive-news-summary-2021-09-10
******************************************Also see my other blogs. Main ones below:
http://edwatch.blogspot.com (EDUCATION WATCH)
http://antigreen.blogspot.com (GREENIE WATCH)
http://pcwatch.blogspot.com (POLITICAL CORRECTNESS WATCH)
http://australian-politics.blogspot.com/ (AUSTRALIAN POLITICS
http://snorphty.blogspot.com/ (TONGUE-TIED)
*************************************
Friday, September 10, 2021
Pfizer breakthrough as drugmaker one step closer to rolling out Covid-killing wonder pill
PFIZER has made another breakthrough in their historic fight against COVID-19 after announcing they are one step closer to rolling out a coronavirus-killing wonder pill.
The simple pill is designed to be taken at home in the early stages of COVID-19 infection and it could be another big step forward in the fight against the virus. We have seen over the last months a variety of treatments for the virus, including the Oxford-AstraZena vaccine, created by British scientists.
While vaccines are highly effective at reducing the risk of death or getting seriously ill from contracting the virus, and things like ventilators can help to save lives to people who have been hospitalised, there is also a need for effective oral treatment.
There are currently a few pills being developed that are aimed at treating Covid, but Pfizer's is the first one to reach advanced human trials.
The drugmaker plans to trial the drug on 1,140 adults infected with the virus who are not considered to be high risk and are unlikely to suffer from serious illness or death if they catch COVID-19.
The pill, which is technically called PF-07321332, is in a category of antiviral agents called protease inhibitors.
Proteases are enzymes that are used for viral replication and protease inhibitors have been developed in the past to treat deadly diseases like and hepatitis C and HIV/AIDs.
Pfizer said in a statement: "Protease inhibitors, like PF-07321332, are designed to block the activity of the main protease enzyme that the coronavirus needs to replicate.
"Co-administration with a low dose of ritonavir is expected to help slow the metabolism, or breakdown, of PF-07321332 in order for it to remain in the body for longer periods of time at higher concentrations, thereby working continuously to help combat the virus.
"Ritonavir has previously been used in combination with other antivirals to similarly inhibit metabolism."
Martin J. Blaser, director of the Center for Advanced Biotechnology and Medicine at Rutgers University, also hailed the breakthrough.
He said: "The hope is that the Pfizer drug and ritonavir together will sufficiently inhibit the SARS-CoV-2 protease to slow down the virus enough that [the] host's immune defences will overcome and eliminate it."
***********************************
There Are Better Ways to Fight COVID-19 Than Mask Mandates
Even though policy should be based on accurate data, the Centers for Disease Control and Prevention is failing to accurately justify its guidance that vaccinated people wear masks.
The data clearly show that the vaccine helps people more than previous interventions, including mask mandates, and that the risk of dying from COVID-19 for the vaccinated is extremely low.
The CDC should follow the science, be transparent, and base all guidance on the data.
Originating in India, the delta variant is now the primary strain of COVID-19 here in the United States. A number of states, including Alabama, Louisiana, Florida, and Texas, have been experiencing surges in new cases and hospitalizations.
Given such concerns, the CDC investigated the delta variant’s spread last month. In a Morbidity and Mortality Weekly Report released on July 30, a number of researchers examined COVID-19 spread last month during a variety of festivities in Barnstable County, Massachusetts.
The authors made a number of claims, including that 74% of those who tested positive for COVID-19 after the festivities were fully vaccinated.
Not surprisingly, this statistic made the news headlines. For example, the day the study was released, an article on CNBC.com reported: “CDC study shows 74% of people infected in Massachusetts Covid outbreak were fully vaccinated.”
Given how much attention the analysis had gotten, my colleague Norbert Michel and I decided to take a look at the study in critical detail. After all, public policy should be informed by credible and accurate analysis.
We found that the study failed to look at the question at hand with sufficient rigor and does not provide support for the study’s main recommendation about mask wearing among the vaccinated.
Among the 469 who tested positive, 74% indeed had been vaccinated. However, as we discussed in our report, the data that this estimate is based on are not representative of the Barnstable attendees, let alone of the entire country. Therefore, it would be a mistake to use those estimates to make inferences of the broader American population.
Second, there’s a more fundamental question the authors neglected to look at: Infection rates in the broader context of the number of people who actually attended the festivities, both vaccinated and unvaccinated.
We also examined this question, making a variety of assumptions on available data and information. Assuming an attendance of 60,000, as has been suggested by a number of people, and a vaccination rate of 90% of attendees, we found the following infection rates.
At the time of publication, the state of Massachusetts and Barnstable County had adult vaccination rates above 74%, and Provincetown itself had a rate of 90%.
As the festivities may have included some out-of-state visitors as well, we decided to estimate the percentage of infections under vaccination rates between 60% and 98%.
Although some research has indicated that the vaccines may have slightly less efficacy in preventing infection against the delta variant than prior variants, the vaccines are nevertheless highly effective at preventing hospitalization and death.
Furthermore, as a result of the CDC’s “study” on Barnstable, Massachusetts, one of the policy recommendations is that the fully vaccinated continue to wear masks in areas of high disease proliferation.
However, as Michel and I have illustrated in prior work, mask mandates do not meaningfully impact case proliferation. In an earlier Heritage Foundation special report, we statistically examined the impact of an executive order signed by Kansas’ Democratic governor, Laura Kelly, allowing each of the state’s 105 counties to take part in an optional mask mandate last year.
Our analysis did find slightly less case growth at times in the cases in which masks were mandated. However, on a monthly basis, those differences were not statistically significant and, most alarmingly, per capita cases and deaths continued to grow in both groups through most of the second half of last year.
Vaccines, on the other hand, have been largely successful, as is evident by the steep drops in case counts, followed by increases in vaccination rates over the years. Bottom line: Unlike masks, the statistics on vaccine efficacy are solid and well-established.
Of course, there will continue to be breakthrough cases, but the CDC’s own data indicate that the truth is the vaccines have had over 90% efficacy against hospitalization and death.
Not surprisingly, however, among the unvaccinated, COVID-19 can still be quite deadly, especially for the elderly and those with chronic conditions. The following chart puts those odds in perspective with other causes of death.
As the chart illustrates, however, the odds of dying of COVID-19 despite being fully vaccinated, although not zero, are slim to none. In fact, those under 65 have significantly higher odds of getting struck by lightning.
Bottom line: Mask mandates on the vaccinated will only increase vaccine hesitancy and thus only prevent our country from putting this pandemic behind us.
One of the best ways to encourage the vaccine hesitant to reconsider is not mandates, but rather to equip them with good statistical analysis, so they can work with their doctors to make informed decisions. The CDC would do well to fix this failure.
https://www.heritage.org/public-health/commentary/there-are-better-ways-fight-covid-19-mask-mandates
******************************************Also see my other blogs. Main ones below:
http://edwatch.blogspot.com (EDUCATION WATCH)
http://antigreen.blogspot.com (GREENIE WATCH)
http://pcwatch.blogspot.com (POLITICAL CORRECTNESS WATCH)
http://australian-politics.blogspot.com/ (AUSTRALIAN POLITICS
http://snorphty.blogspot.com/ (TONGUE-TIED)
*************************************
Thursday, September 09, 2021
Antibiotics and bowel cancer
I no longer post regularly on my Food & Health blog but I have just put up something there that should be of general interest -- An article about a link between antibiotics and bowel cancer
*******************************
AstraZeneca boss says booster jabs may not be needed
Booster vaccines may not be needed for everyone in Britain, the boss of AstraZeneca has said.
Chief executive Pascal Soriot said that rolling out third doses too quickly would be an “unnecessary burden” on the NHS.
He also called for patience from the government, stressing the UK was “a few weeks away” from having a definitive answer on the effectiveness of two doses in providing long-lasting protection.
Mr Soriot said that shortly it will have been six months since the first people had their second jabs so the data would give “a clearer picture of the immune response needed to provide continued, protective immunity”.
Writing in the Daily Telegraph, Mr Soriot, alongside the company’s executive vice-president of biopharmaceuticals R&D Sir Mene Pangalos, said: “Moving too quickly to boost across the entire adult population will deprive us of these insights, leaving this important decision to rest on limited data.
“A third dose for all may be needed, but it may not. Mobilising the NHS for a boosting programme that is not needed would potentially add unnecessary burden on the NHS over the long winter months.
“Because NHS staff and resources are scarce, another national mobilisation would potentially leave us with fewer resources for cancer screenings and the other care provided by doctors and nurses each day.”
Their comments come as Health Secretary Sajid Javid said on Wednesday he is “very confident” there will be a booster programme for coronavirus, but is awaiting advice from the Joint Committee on Vaccination and Immunisation (JCVI).
He told Sky News: “In terms of who actually gets it and when, we’re waiting for final advice which could come across, certainly, in the next few days from the JCVI.”
He said the advice is expected to include information on whether people should get different vaccines to the ones they have already had or the same ones, and added: “I’m confident that we can start the booster programme this month.”
However WHO chief Tedros Adhanom Ghebreyesus said last month that booster shots should be delayed in highly vaccinated countries, like the UK, and the doses prioritised for countries will low vaccination rates.
He added that there is a debate in the scientific community about whether “booster shots are effective at all”.
The UK’s chief medical officers are currently reviewing the benefits of vaccinating 12 to 15-year-olds after the JCVI declined to recommend a widespread rollout to the age group on health grounds alone.
Mr Javid has said he expects to hear from the UK’s chief medical officers in the coming days on their views as to whether there should be a mass rollout of Covid-19 vaccines for young people.
He told Sky News: “I want to give them the breathing space, it’s their independent view and that’s exactly what it should be. But I would expect to hear from them in the next few days.”
https://au.yahoo.com/news/astrazeneca-boss-says-booster-jabs-094117895.html
******************************************Dr. Scott Atlas, Others Throttle Bangladesh Mask Study: 'Extremely Weak Tea'
I rubbished this study on 3rd.
Dr. Scott Atlas, former chief of neuroradiology at Stanford University Medical Center and a senior fellow at Stanford’s Hoover Institution, called a recent study purporting to measure the effect of masking on curbing the spread of Covid-19 in Bangladeshi villages "extremely weak tea" during a Fox News appearance earlier this month.
The randomized trial, the results of which were posted September 1 by the nonprofit organization Innovations for Poverty Action and are currently being peer reviewed, measured over 340,000 people in 600 villages. It claims to show that an increase in the usage of surgical masks can lead to a reduction in the spread of the virus in certain age groups (via NBC News).
For five months beginning last November, [study co-author Mushfiq] Mobarak and his colleagues tracked 342,126 adult Bangladeshis and randomly selected villages to roll out programs to promote their usage, which included distributing free masks to households, providing information about their importance and reinforcing their use in the community.
Among the roughly 178,000 individuals who were encouraged to wear them, the scientists found that mask-wearing increased by almost 30 percent and that the change in behavior persisted for 10 weeks or more. After the program was instituted, the researchers reported an 11.9 percent decrease in symptomatic Covid symptoms and a 9.3 percent reduction in symptomatic seroprevalence, which indicates tBangladeshhat the virus was detected in blood tests.
While the effect may seem small, the results offer a glimpse of just how much masks matter, Mobarak said.
"A 30-percent increase in mask-wearing led to a 10 percent drop in Covid, so imagine if there was a 100-percent increase — if everybody wore a mask and we saw a 100-percent change," he said.
The scientists said masks significantly reduced symptomatic infections among older adults, and found that surgical masks were more effective than cloth versions.
Appearing earlier this month on Fox News' "The Ingraham Angle," Atlas called the fact that the study was randomized "important" before citing a similarly randomized study from Denmark conducted last year that showed that "individuals wearing masks do not have a lower risk of infection testing for virus than people not wearing masks."
"This is a different type of study," said Atlas, a frequent and early lockdown critic who briefly served as a member of former President Donald Trump's White House coronavirus task force last year. "This tests to see if people in a village get symptomatic Covid if the villagers wear masks versus other villages that don’t wear masks as much."
The Hoover Institution fellow went on to describe two results from the study before explaining why he feels it's hardly the definitive evidence pro-maskers have been searching for these past 18 months.
One, in people defining Covid as symptoms plus anti-bodies, there is no evidence that cloth masks have any impact, no significant impact with cloth masks for people who have Covid as defined by Covid symptoms with antibody documentation. So cloth masks are worthless according to this study.
The second part is the surgical mask study. And the surgical mask study shows that there is from my reading here about an 11% decrease in individuals having symptomatic Covid with antibodies. 11%. And basically only older people. So what this shows you after all is said and done is it confirms that cloth masks are worthless. It shows - if you take the data at face value - a very minimal impact, 11%, decrease in symptomatic cases in mask usage by the village.
And so, you know, of all the clamoring for something desperately to show that masks work, this is what I would call extremely weak tea. In fact, it confirms the reason why we have seen all over the world and in the United States that mask usage by the population does not significantly stop the spread of the virus.
It's being oversold, but people are desperate to find some pebble somewhere that shows masks work.
Atlas, by far, wasn't the only critic. Professor Francois Balloux, director of the UCL Genetics Institute and professor of computational biology at University College London, tweeted that it's "not obvious" from the study that masks are "statistically significantly associated with reduced transmission at the level of the population."
Nick Hudson, chairman of Pandata.org (PANDA), tweeted a blog post by Substack writer el gato malo titled, "bangladesh mask study: do not believe the hype," calling it "sound commentary."
From el gato malo's analysis:
To claim that masks caused any given variance in outcome, you need to isolate masks as a variable. They didn’t. This was a whole panoply of interventions, signage, hectoring, nudges, payments, and psychological games. It had hundreds of known effects and who knows how many unknown ones.
We have zero idea what’s being measured and even some of those variables that were measured showed high correlation and thus pose confounds. when you’re upending village life, claiming one aspect made the difference becomes statistically impossible. the system becomes hopelessly multivariate and cross-confounded.
The authors admit it themselves (and oddly do not seem to grasp that this invalidates their own mask claims)
Gato's post has gotten lots of attention on Twitter for its thoroughness.
Harvard professor Dr. Martin Kulldorff called it "odd" that "mask advocates are excited by this study."
*******************************************
IN BRIEF
Texas governor signs GOP voting restrictions voting integrity into law (AP)
Dr. Anthony Fauci faces call to resign and answer for report about U.S. government-funded Wuhan research (Daily Wire)
Who’d a thunk it? Minnesota man freed by Kamala Harris-supported bail fund now charged with murder (Fox News)
Four Taliban members swapped for Bowe Bergdahl now in Afghan government (NY Post)
A trip down memory lane: Barack Obama’s prisoner swap broke the law, GAO says (NPR)
Chinese muscle in on Afghanistan’s rare earth mineral deposits, creating more headaches for Biden (Washington Times)
ICE counts 463 sanctuary jails and prisons in U.S. — and another 156 give limited cooperation (Washington Times)
House Republican demands Hunter Biden’s art dealer assist in investigating White House corruption (Breitbart)
Democrats poised for bitter September spending battle within their own ranks (Washington Examiner)
Human Rights Campaign fires its president, Alphonso David, after he advised Andrew Cuomo during sexual misconduct scandal (Daily Wire)
ACLU denounced pandemic mandates before COVID-19 (Fox News)
South Dakota governor bans telemedicine abortions (National Review)
Oregon residents outraged by video of flagrant shoplifting (National Review)
Odds of a “breakthrough” COVID infection worsen with Delta variant (Washington Times)
University of California doctors challenge its vaccine mandate as “irrational” (Just the News)
Biden’s inflation woes persist with production stoppages at “Big Three” automakers (Washington Examiner)
Catholics frustrated as increasing attacks on churches go unnoticed (Washington Times)
******************************************
Also see my other blogs. Main ones below:
http://edwatch.blogspot.com (EDUCATION WATCH)
http://antigreen.blogspot.com (GREENIE WATCH)
http://pcwatch.blogspot.com (POLITICAL CORRECTNESS WATCH)
http://australian-politics.blogspot.com/ (AUSTRALIAN POLITICS
http://snorphty.blogspot.com/ (TONGUE-TIED)
*************************************
Wednesday, September 08, 2021
'Mu' variant has been detected in EVERY US state except Nebraska
The Mu variant of COVID-19- which scientists fear could be more transmissible than Delta - has now been detected in all U.S. states with the exception of Nebraska.
Florida and California have reported 384 variant cases- the highest numbers among the 49 infected U.S. states.
Los Angeles County reported close to half of the California cases with 167.
The new cases however only reflect 0.2 percent of total variant samples from the state of California between June and August.
Alaska previously had the highest number of Mu variant cases with 146. That represented four per cent of all cases recorded in the isolated state.
Other U.S. states have also shared their Mu numbers, with 42 in Maine, 73 in Connecticut and 39 in Hawaii, according to Newsweek.
The Mu variant- which was identified in Colombia in January - has spread to 41 different countries including the United States, and is also feared to potentially be vaccine-resistant.
The variant became of interest due its potential to become more transmissible and vaccine resistant as discovered by the World Health Organization on August 30.
The CDC, however, has not shared this analysis.
Director of LA County Public Health Barbara Ferrer said in a statement: 'The identification of variants like Mu, and the spreading of variants across the globe, highlights the need for L.A. County residents to continue to take measures to protect themselves and others.
'This is what makes getting vaccinated and layering protections so important. These are actions that break the chain of transmission and limits COVID-19 proliferation that allows for the virus to mutate into something that could be more dangerous.'
Dr. Anthony Fauci also commented on the Mu variant claiming that it would not be the next dominant COVID strain. 'Even though it has not in essence taken hold to any extent here we always pay attention to at all times variants,' he said. 'We don't consider it an immediate threat right now.'
This mutant strain was first spotted in Colombia in January. It has since spread to more than 40 countries including the UK, US, France, Japan and Canada.
Is it increasing in prevalence?
There have been 4,000 cases detected to date, but this is thought to be an underestimate because many countries that have suffered outbreaks do very little surveillance for variants.
The number of cases blamed on the variant declined globally last month, amid the spread of the Delta strain.
In Colombia — where it was first detected — it is still behind around six in ten infections.
Can the strain dodge vaccine triggered immunity?
The variant carries the mutation E484K, which can help it escape antibodies.
This change is also found on the South African 'Beta' variant and Brazilian 'Gamma' variant.
A PHE study previously suggested it could make vaccines less effective. But UK health chiefs said more research was needed.
The variant has been further described by Fauci as 'a constellation of mutations that suggest that it would evade certain antibodies, not only monoclonal antibodies, but vaccine and convalescent serum- induced antibodies.'
The peak of Mu variant cases were present in mid-July and have been declining since. However, the fear is that the variant will strengthen again in the future.
The nation has eclipsed an average of 1,500 COVID-19 deaths per day, the first time the mark has been reached in six months - since the vaccination drive began in earnest.
Figures from Johns Hopkins University released early Tuesday showed that the US has recorded 40,018,318 cases of COVID since the pandemic began, with 647,072 people known to have lose their lives as a result.
When the 1,500 figure was last reached in March, though, the vaccines were not as widely available as they are now.
The Centers for Disease Control and Prevention (CDC) also reports that deaths increased by 131 percent in August compared to previous months.
COVID-19 cases are also 300% higher this year when compared to last year's labor day weekend - before any vaccines were available.
Hospitalizations nationwide have spiked as well, with August having double the amount of COVID-19 patients admitted than June did.
The rise in deaths corresponds with a rise in hospitalizations.
More than 102,000 American are hospitalized with the virus, and 75 percent of hospital beds nationwide are currently in use.
Nationwide, the U.S. has recorded over 40 million COVID-19 cases and 648,000 deaths from the virus, the most of any nation in the world in both categories
https://www.dailymail.co.uk/news/article-9964415/Mu-variant-detected-U-S-state-except-Nebraska.html
*****************************************Delta transmission in children low, causes mild illness, report finds -- Australian report
There has been a five-fold increase in the spread of COVID-19 in educational settings but only 2 per cent of children who caught it during the latest outbreak have been hospitalised, and most experienced mild or no symptoms, a new report from the National Centre for Immunisation and Research has found.
Transmission between children has also been low, it found.
The report looked at transmission of COVID-19 in schools and households between June 16 and July 31, and found that the NSW experience was consistent with overseas studies showing the Delta variant was more transmissible and led to more infections among children and young people.
Professor Kristine McCartney, a specialist at The Sydney’s Children’s Hospital at Westmead, said the rate of transmission between children was low, and most of the transmission was between unvaccinated adults. “The spread between children themselves was very low,” she said.
“We’re very lucky to know, and it’s consistent with data over the course of the pandemic, that COVID-19 is mild among children.
“Only around 2 per cent will require hospitalisation and, for many of those 2 per cent, it’s for monitoring and social care. Unfortunately, often their parents are unwell with COVID-19 and that’s why they’re being cared for in the hospital.”
The report found that across 19 schools and 32 early childcare services, there were 59 people - 34 students and 25 staff members - who attended while infectious. From those primary cases, 2347 people were considered close contacts.
The overall transmission rate at early childhood centres was 4.7 per cent, with 106 secondary cases involving 69 students and 37 staff members. Transmission occurred in 19 of the 51 settings. The highest transmission in early childhood settings was between staff members, and from a staff member to children.
Transmission was lower in schools, the report said, at a rate of 2.1 per cent; there were nine secondary cases in 728 close contacts. “This was likely due to the school holiday period and subsequent limited onsite attendance in term 3,” the report said.
Dr Archana Koirala, a paediatric infectious disease specialist and University of Sydney lecturer, said full participation in education services was essential for children to learn and develop socially.
“These results should give confidence to families, schools and the community that we have robust evidence on how the Delta variant behaves in children,” she said.
The study found the so-called attack rate - or the transmissibility of the strain - was highest between adults (11.2 per cent) and second highest from adults to children (seven per cent). Between children it was 1.6 per cent and from children to adults it was 1.5 per cent.
**********************************************
Toxic Double Standards Get More Blatant
Let’s take the shooting of Ashli Babbitt. When one compares it to some other high-profile shootings, like the Michael Brown case, for instance. Officer Darren Wilson of the Ferguson Police Department went through an ordeal, even though Brown had tried to take his gun, an action that warrants the use of deadly force.
Did Wilson ever get the “puff piece” interview with Lester Holt that the cop who pulled the trigger on Ashli Babbitt did? Many of the voices who condemned the clearly justified actions of Wilson also seemed to have no problems with the shooting of Babbitt. If anything, if it had been Donald Trump’s reelection that would have been confirmed by the electoral vote count, and a Capitol Police officer had fired a fatal shot in circumstances similar to those surrounding Ashli Babbitt, how would that have been covered by the biased media outlets?
The toxic double standards don’t stop there. We could also look at a tale of two lieutenant colonels. Marine Stuart Scheller called for accountability in the wake of the horrific bombing that killed 10 Marines, two soldiers, and a Navy corpsman during the dishonorable debacle caused by Joe Biden’s betrayal in Afghanistan and was immediately fired. He now expects to be court-martialed.
Contrast that to the hero treatment Alexander Vindman got for what Byron York describes as his political gamesmanship on behalf of the deep state. Never mind that Vindman was among a bunch of bureaucrats actively undermining his commander-in-chief. Just imagine the way the usual suspects at MSNBC would have reacted if Vindman had tried to mess with Barack Obama’s Iran giveaway or Iraq withdrawal the way he did with Trump’s policy vis-Ã -vis Ukraine.
Speaking of Trump’s Ukraine policy, remember how so many of those “news” outlets harped on that phone call with Ukraine’s president? Well, consider the lack of curiosity about Biden’s phone call this past July with the president of Afghanistan, one in which he allegedly expressed knowledge of the precarious situation preceding the dishonorable debacle the pullout became. If Biden is held to the standard Democrats demanded of Trump, he’d be impeached and removed.
When combined with the many earlier cases of double standards, not to mention the lies and hateful rhetoric, abuses, and other assaults that defy any sense of fairness or common sense, it’s clear that much of the establishment media — and other defenders of so-called “norms” — have been running on double standards for a long time. The thing is, grassroots Patriots are tired of it, and they’re increasingly losing respect for those who not only impose double standards but also those who refuse to call them out. In the long run, that will have some dire consequences for the country.
https://patriotpost.us/articles/82512-toxic-double-standards-get-more-blatant-2021-09-07
***************************************IN BRIEF
President Biden’s approval tanks; only two others have had lower ratings at this point (Fox News)
DOJ vows not to protect preborn babies in Texas (Axios)
Only off by … well, nearly 100%: AP adds embarrassing correction to article claiming 70% of calls to Mississippi poison control were about Ivermectin ingestion (Daily Wire)
The end of enhanced unemployment benefits brings hope to small businesses (Fox Business)
In wake of Andrew Cuomo scandal, entire board resigns from Time’s Up, whose top leaders aided and abetted the disgraced ex-governor (Daily Wire)
Patriotic restaurants across America honored our troops killed in Kabul by reserving a table for them and setting out 13 beers
Apple wisely delays iPhone photo-scanning plan amid fierce backlash (AP)
Policy: Social Security bailout will create another set of problems (Market Watch)
******************************************
Also see my other blogs. Main ones below:
http://edwatch.blogspot.com (EDUCATION WATCH)
http://antigreen.blogspot.com (GREENIE WATCH)
http://pcwatch.blogspot.com (POLITICAL CORRECTNESS WATCH)
http://australian-politics.blogspot.com/ (AUSTRALIAN POLITICS
http://snorphty.blogspot.com/ (TONGUE-TIED)
*************************************
Tuesday, September 07, 2021
Promising drug a new weapon in curbing COVID’s worst effects
Comment from Australia
Yesterday 1281 new cases of COVID-19 were reported in NSW. By October many of these will be seriously ill in hospital, some in intensive care, and a few will die. Others will progress to indefinite multifaceted illness called “Long COVID”.
Can this miserable trajectory be modified, while we wait for the vaccination drive to “stop the spread”?
Clinical trials and overseas experience with a class of therapeutic drugs called monoclonal antibodies suggests that it can – but only when they are given early. COVID-19 patients treated in a trial of one such drug called Sotrovimab exhibited an 79 per cent relative reduction in hospitalisation and deaths. In March, the independent regulator halted patient recruitment because of “profound efficacy”. Even with small numbers, before the Delta outbreak, the statistics were persuasive.
The first of 7700 doses of Sotrovimab quietly slipped into Australia three weeks ago. We have waited some time. It now has Therapeutics Goods Administration provisional approval for vulnerable patients, such as the elderly and immunocompromised. It is being used in Shepparton, Victoria. What are the plans for NSW?
Sotrovimab is the latest and, possibly, best therapeutic monoclonal antibody to inhibit the COVID-19 virus attaching to human tissue. The US Federal Drug Authority authorised its emergency use in May. The headline cost is $US2100 a dose, and it’s free to vulnerable Americans.
President Trump was treated with, among other drugs, a duo of anti-COVID monoclonal antibodies labelled Regeneron, similarly authorised in America last November. The US National Institute of Health recommends either drug for vulnerable patients. Don’t mention them in the same breath as ivermectin or hydroxychloroquine.
With COVID on the march in America, antibody distribution has massively scaled up. The Texas state government has just established public antibody infusion centres.
Intravenous antibody infusions take an hour, in infectious patients. No small short-term imposition on overstretched health systems. Yet, one which could prevent a much greater hospital overload in the months which follow. Perhaps a treatment centre on an oval near a hospital should be considered. Like the precautionary Surge Centre in Canberra.
The United Arab Emirates, where Delta is prevalent, and logistics are military-grade, announced striking results, with no deaths among 6175 COVID-19 patients treated in July.
Nevertheless, and crucially, immunologists worry that indiscriminate use of a single antibody such as Sotrovimab might cause resistant variants to emerge and leak into the community. It is no substitute for vaccination. The ethical issues are obvious.
Monoclonal antibodies attack and disable unwanted targets. Think Herceptin for breast cancer, Keytruda for melanoma , Emgality for migraine and Humira for arthritis - all monoclonals, each created or modified for a very specific target. Each is a feat of structural molecular engineering.
It was Britain’s Cambridge scientist, Sir Gregory Winter, who devised and developed the generic technology that underpins monoclonal antibodies. At first, business failed to see their potential. And so, as he recounted in his 2018 Nobel address and at Sydney University in 2019, it was seed-funding from the Australian racing industry which launched monoclonal antibodies to market. The deal was done on a boat on Sydney Harbour. He overheard a whispered comment “Let’s give Greg the money. Let’s see how the boffin trots”. Annual monoclonal revenues now well exceed $100 billion, to untold human benefit.
The Australian perspective has come full circle. Professor Daniel Christ is a former PhD student of Winter’s and is now at the Garvan Institute. He sees a way around this antibody resistance problem. And he looks to the experience in treating HIV infection with three different drugs which curbed that epidemic.
Since early 2020, his team has worked flat out to create monoclonals against COVID-19. They now have three antibodies which are more potent than Sotrovimab in vitro, When used together, they should be very resistant to mutation escape.
If these ventures succeed, Australians will have good reason to be thankful for investment in science.
***************************************
New study finds AstraZeneca more effective against Delta strain
Deakin University Chair of Epidemiology Professor Catherine Bennett says the AstraZeneca vaccine is more effective than others against the Delta strain of COVID-19 in certain instances.
Professor Bennett cited a new study from Bahrain, conducted in partnership with Columbia University in the United States, which found “extraordinary differences” when comparing a number of vaccines.
“They found for those over 50 … 44 times less likely to end up in ICU if you have AstraZeneca, and I think it’s 33 times less likely with Pfizer,” Professor Bennett told Sky News host chris Kenny.
“Both extraordinarily effective, but AstraZeneca actually has the edge on that.”
********************************************
Suicide a bigger problem than Covid
Comment from Australia
One-in-four Australians say they know someone who died by suicide or attempted to take their own life in the past year – equivalent to five million adults – a new survey has found.
Suicide Prevention Australia chief executive officer Nieves Murray said major social and economic events had historically influenced suicide rates.
“We know social and economic isolation are the biggest drivers of suicide rates and Covid-19 has seen Australians subject to 18 months of rolling lockdowns and disruption to their personal lives, employment and businesses,” she said.
“We’ve seen how quickly Covid-19 cases can get out of hand and we need to have the same national policy focus and vigilance to stop suicide rates doing the same.”
The survey commissioned by Suicide Prevention Australia and completed by YouGov in August, found 25 per cent of adult Australians surveyed knew someone who had died by suicide or attempted to take their own life in the previous 12 months. About 15 per cent knew the person directly, while another 11 per cent knew them indirectly.
About 16 per cent said they had sought help or searched for advice from a suicide prevention service in the past 12 months, about 16 per cent said they had indirectly sought help.
Most people thought “social isolation and loneliness” was the biggest risk to suicide in the next 12 months, with 64 per cent rating it as an issue.
This was followed by unemployment and job security (58 per cent); family and relationship breakdowns (57 per cent); cost of living and personal debt (55 per cent); and drugs and alcohol (53 per cent).
While the latest data from suicide registers in New South Wales, Victoria and Queensland do not show an increase in suspected suicide deaths in 2020, or since the Covid-19 pandemic began, Ms Murray said the number of deaths in 2019 had been the highest recorded in Australia, growing from 3093 in 2015, to 3318 in 2019.
“There have never been more lives lost to suicide in this country,” Ms Murray said.
Those surveyed were particularly worried about the suicide risk among young people aged 12-25 years old (42 per cent), followed by middle aged Australians aged 25-55 years old (29 per cent) and men (29 per cent).
Other people thought to be at risk were those living in regional and rural areas (24 per cent), LGBTQI Australians (21 per cent), Indigenous Australians (18 per cent) and those aged over 55 (18 per cent).
The survey also supported a stand-alone national suicide prevention act, similar to one introduced in Japan, which would require the Federal Government to consider and mitigate suicide risks when making all decisions, not just ones related to health.
About 66 per cent thought Australia should introduce similar legislation.
Ms Murray said legislation was the best prevention against suicide rates increasing.
“The heightened economic and social threat posed by Covid-19 means we cannot afford to wait to legislate,” Ms Murray said.
“Australia needs a national suicide prevention act and we need to act now. “We all have a role to play in preventing suicide. An act will legislate a whole-of-government priority to prevent suicide and focus the attention of every agency to address the risk of suicide across our community.
“Suicide prevention isn’t limited to health portfolios. Housing is suicide prevention, employment is suicide prevention, finance is suicide prevention, and education is suicide prevention.”
The organisation noted that more than three times the amount of people died from suicide in 2019 (3318 people) than have died from Covid-19 since the pandemic began (1019 people as of September 2).
******************************************
Also see my other blogs. Main ones below:
http://edwatch.blogspot.com (EDUCATION WATCH)
http://antigreen.blogspot.com (GREENIE WATCH)
http://pcwatch.blogspot.com (POLITICAL CORRECTNESS WATCH)
http://australian-politics.blogspot.com/ (AUSTRALIAN POLITICS
http://snorphty.blogspot.com/ (TONGUE-TIED)
*************************************
Subscribe to:
Posts (Atom)
